Skip to main content
Journal cover image

High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study.

Publication ,  Journal Article
Peters, WP; Stuart, A; Klotman, M; Gilbert, C; Jones, RB; Shpall, EJ; Gockerman, J; Bast, RC; Moore, JO
Published in: Cancer Chemother Pharmacol
1989

A total of 23 patients were treated at five dose escalations with high-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. The maximum tolerated doses of cyclophosphamide, cisplatin, and melphalan were 5,625, 180, and 80 mg/m2, respectively. The dose-limiting toxicity was cardiac toxicity. Objective tumor regression occurred in 14 of 18 evaluable cases, with a median duration of 3.5 months. Pharmacokinetic evaluation of melphalan in 20 patients revealed a dose-related increase in maximum plasma concentration (Cmax) and area under the curve (AUC). Perturbation of the melphalan plasma half-life and AUC, associated with severe toxicity, resulted when renal insufficiency occurred. The results suggest that high-dose combination cyclophosphamide, cisplatin, and melphalan produces frequent, rapid responses in breast cancer, melanoma, and sarcoma, although with significant extramedullary toxicity. The pharmacokinetics suggest that modification of the treatment schedule may result in a reduction of treatment-related toxicity.

Duke Scholars

Published In

Cancer Chemother Pharmacol

DOI

ISSN

0344-5704

Publication Date

1989

Volume

23

Issue

6

Start / End Page

377 / 383

Location

Germany

Related Subject Headings

  • Transplantation, Autologous
  • Sarcoma
  • Oncology & Carcinogenesis
  • Neoplasms
  • Neoplasm Metastasis
  • Melphalan
  • Melanoma
  • Humans
  • Female
  • Cyclophosphamide
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Peters, W. P., Stuart, A., Klotman, M., Gilbert, C., Jones, R. B., Shpall, E. J., … Moore, J. O. (1989). High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. Cancer Chemother Pharmacol, 23(6), 377–383. https://doi.org/10.1007/BF00435840
Peters, W. P., A. Stuart, M. Klotman, C. Gilbert, R. B. Jones, E. J. Shpall, J. Gockerman, R. C. Bast, and J. O. Moore. “High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study.Cancer Chemother Pharmacol 23, no. 6 (1989): 377–83. https://doi.org/10.1007/BF00435840.
Peters WP, Stuart A, Klotman M, Gilbert C, Jones RB, Shpall EJ, et al. High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. Cancer Chemother Pharmacol. 1989;23(6):377–83.
Peters, W. P., et al. “High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study.Cancer Chemother Pharmacol, vol. 23, no. 6, 1989, pp. 377–83. Pubmed, doi:10.1007/BF00435840.
Peters WP, Stuart A, Klotman M, Gilbert C, Jones RB, Shpall EJ, Gockerman J, Bast RC, Moore JO. High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. Cancer Chemother Pharmacol. 1989;23(6):377–383.
Journal cover image

Published In

Cancer Chemother Pharmacol

DOI

ISSN

0344-5704

Publication Date

1989

Volume

23

Issue

6

Start / End Page

377 / 383

Location

Germany

Related Subject Headings

  • Transplantation, Autologous
  • Sarcoma
  • Oncology & Carcinogenesis
  • Neoplasms
  • Neoplasm Metastasis
  • Melphalan
  • Melanoma
  • Humans
  • Female
  • Cyclophosphamide